TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02554305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fusion oxygenation system
Description: The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Affinity oxygenation system
Description: The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
Study: NCT04321343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL065
Description: PXL065 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL065
Description: PXL065 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL065
Description: PXL065 oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study: NCT01323296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
Study: NCT00998738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixabepilone
Description: Given IV
Study: NCT01960010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIM-D3 Ophthalmic Solution
Description: 1% MIM-D3 dosed BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle dosed BID
Study: NCT00765765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dose escalation from 200 mg po qd to 200 mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
Study: NCT01835444

Intervention type: OTHER
Intervention: PA/MD model
Description: Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
Study: NCT02643550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD(L)1
Study: NCT01262430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OtisMed
Description: OtisMed Custom-fit Shapematching Guides

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Assisted Surgery (CAS)
Description: Stryker Navigation System
Study: NCT03880565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation
Description: Early use of ECMO

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Advanced Cardiac Life Support (ACLS) Resuscitation
Description: Standard life support resuscitation
Study: NCT01567514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer cement lining
Description: Resin-modified glass ionomer lining

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Glass ionomer cement lining
Description: Resin-modified glass ionomer lining
Study: NCT04026425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two-day cardiopulmonary exercise test
Description: A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-day cardiopulmonary exercise test
Description: A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
Study: NCT02232347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Study: NCT01286350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FL3X: Flexible Lifestyle Empowering Change
Description: The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
Study: NCT01902069

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phospholean
Description: Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994).
Study: NCT02733042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered as an IV infusion (250 mL) over approximately 1 hour in duration
Study: NCT01902069

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of rice flour
Study: NCT01809067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender aromatherapy inhalers
Description: Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
Study: NCT02684175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote CI Counseling
Description: The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person CI Counseling
Description: The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
Study: NCT02733042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered as an IV infusion (250 mL) over approximately 1 hour in duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered as an IV infusion (250 mL) over approximately 1 hour in duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered as an IV infusion (250 mL) over approximately 1 hour in duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered as a 30-minute intravenous infusion
Study: NCT01952301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogeneic Collagen Matrix
Description: A type I and III porcine collagen matrix, as cleared by FDA (K012423)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Autogenous, full-thickness soft tissue graft harvested from patient's palate.
Study: NCT02600858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper limb feeding training
Description: Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Upper limb feeding training
Description: Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days.
Study: NCT03153852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Jessner's solution
Description: Modified Jessner's solution will be applied on the right side until frosting
Study: NCT04594551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free
Description: Pharmaceutical form:freeze-dried - Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine
Description: Pharmaceutical form:freeze-dried - Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rabies immunoglobulins
Description: Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human rabies immunoglobulins
Description: Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
Study: NCT04232748

Intervention type: DRUG
Intervention: first line systemic treatment for colorectal cancer
Description: systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
Study: NCT03153852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Description: Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
Study: NCT03963882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two cycles of neoadjuvant chemotherapy
Description: Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two cycles of neoadjuvant chemotherapy
Description: Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two cycles of neoadjuvant chemotherapy
Description: Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First imaging evaluation
Description: First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First imaging evaluation
Description: First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First imaging evaluation
Description: First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First imaging evaluation
Description: First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Second imaging evaluation
Description: Second imaging evaluation consists of pelvic magnetic resonance imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Second imaging evaluation
Description: Second imaging evaluation consists of pelvic magnetic resonance imaging
Study: NCT06656858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching
Description: Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF stretching
Description: PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching with BFR
Description: Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching with BFR
Description: PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
Study: NCT05181566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement arthroplasty using conventional acetabular cup
Description: In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
Study: NCT02301975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
Description: FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation powders via ELLIPTA inhaler
Description: Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation powders via ELLIPTA inhaler
Description: Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler
Description: FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
Description: Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Description: FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
Study: NCT03173547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 146-9251 cream
Description: 146-9251 cream contains an active drug and is applied topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream does not contain an active drug and is applied topically.
Study: NCT02834663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
Study: NCT01181700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-00241939 300 ug using inhaler A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: PF-00241939 300 ug using inhaler A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: PF-00241939 300 ug using inhaler A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment D
Description: PF-00241939 300 ug using inhaler B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment E
Description: PF-00241939 300 ug using inhaler B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment F
Description: PF-00241939 300 ug using inhaler B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment G
Description: PF-00241939 300 ug using inhaler B
Study: NCT02728674

Intervention type: OTHER
Group type: OTHER
Intervention: Person in the case is a male.
Description: Person in the case is a male.

Intervention type: OTHER
Group type: OTHER
Intervention: Person in the case is a male.
Description: Person in the case is a male.

Intervention type: OTHER
Group type: OTHER
Intervention: Person in the case is a female.
Description: Person in the case is a female.

Intervention type: OTHER
Group type: OTHER
Intervention: Person in the case is a female.
Description: Person in the case is a female.

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom in the case is breathlessness.
Description: Symptom in the case is breathlessness.
Study: NCT04083495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATLCAR.CD30 T cells
Description: Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
Study: NCT02842931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21
Description: R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21 + auto-SCT
Description: R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mNHL-BFM-90
Description: R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mNHL-BFM-90 + auto-SCT
Description: R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Study: NCT00000264

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.35 g/Kg ethanol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.7 g/Kg ethanol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0 g/Kg ethanol
Study: NCT02714530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tarceva daily during radiotherapy course

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy
Study: NCT03050125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar drop 1
Description: 180 mOsmol sterile saline drops used as a contact lens rewetting drop.
Study: NCT00691379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression